Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02408042
Other study ID # WG2014035
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received March 25, 2015
Last updated June 23, 2017
Start date April 2015
Est. completion date November 2015

Study information

Verified date December 2015
Source Western Regional Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient at least 18 years old and has definitive histologically or cytologically confirmed: classical Hodgkin lymphoma (HL) or diffuse large B-Cell lymphoma (DLBCL) non-Hodgkin lymphoma (NHL).

2. Patient has one or more metastatic lesions >1.5 cm as defined by lymphoma response criteria by PET-CT scan. If CT scan is needed for clarification of findings on PET-CT it may be done additionally. Tumor sites that are considered measureable must not have received prior radiation therapy.

3. Patients can be enrolled only on one of the treatment arms on this trial.

4. The investigator will select the appropriate treatment arm for the patient with the following requirements: (a) Patients cannot have had prior progression or intolerance on the single agent chemotherapy and then enrolled on an arm with that same single agent chemotherapy plus pembro (b) The chemotherapy on the arm selected must be considered standard of care or listed in www.nccn.org for that cancer type.

5. Have recovered from acute toxicities of prior treatment:

- > 3 weeks must have elapsed since receiving any investigational agent.

- > 2 weeks must have elapsed since receiving any radiotherapy, or = 3 weeks or 5 half-lives whichever is shorter for treatment with cytotoxic or biologic agents ( = 6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted.

6. Patient has adequate biological parameters as demonstrated by the following blood counts at time of screening:

7. Absolute neutrophil count (ANC) > 1000/ microliter, platelet count = 75,000/ microliter, hemoglobin = 9 g/dL. Subject can be given packed red blood cell transfusion.

8. Calculated creatinine clearance > 50 ml/min by Cockroft-Gault equation, total bilirubin 1.5 times the upper limit of normal (ULN) range, AST/ALT = 3 times the upper limit of normal (ULN) range.

9. Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the upper limit of normal range, then a free T4 within institutional normal limits is acceptable.

10. At least 100 days must have elapsed in subjects that had a prior autologous transplant.

11. Resolution of prior systemic therapy non-hematologic AE to grade = 2 (except alopecia or correctable electrolyte abnormality with supplementation)

12. Patient has a Karnofsky performance status (KPS) = 60.

13. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 4 months following the last dose of Pembrolizumab, brentuximab vedotin, or for 2 years following the last dose of chemotherapy on this trial, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. If a female subject or female partner of a male subject becomes pregnant during this period then patient will be recommended to seek appropriate obstetric care. The study will not be monitoring subjects or female partners of subjects for pregnancy after the last dose of study drug or chemotherapy.

Exclusion Criteria:

1. Active clinically serious infection > Grade 2.

2. Serious non-healing wound, ulcer, or bone fracture.

3. Patient has known brain metastases.

4. Patient has with myelodysplasia, polycythemia vera, idiopathic thrombocythemia, myelofibrosis, or acute leukemia.

5. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.

6. Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients will be required to be tested for the presence of such viruses prior to therapy on this protocol).

7. Ejection fraction measuring less than 45% (measurement of ejection fraction is required only for subjects with prior anthracycline exposure).

8. Requiring daily corticosteroid dose = 10 mg prednisone or equivalent per day.

9. Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.

10. Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindication or Special Warnings and Precautions sections of the product or comparator SmPC or Prescribing Information.

11. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.

12. Patient will be receiving any other anti-cancer therapy during participation in this trial.

13. Prior treatment with Pembrolizumab is not allowed. Prior receipt of other PD-1 inhibitors or PD-L1 inhibitors is allowed.

14. Active or prior documented autoimmune disease requiring systemic treatment within the past 2 years.

Study Design


Intervention

Drug:
Pembrolizumab

Etoposide

Ifosfamide

Mesna

Carboplatin

Brentuximab vedotin

Rituximab


Locations

Country Name City State
United States Cancer Treatment Center of America @ Western Regional Medical Center Goodyear Arizona

Sponsors (1)

Lead Sponsor Collaborator
Western Regional Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with pembrolizumab (pembro) in subjects with advanced lymphoma and complete remission by Revised Response Criteria for Malignant Lymphoma. up to 12 weeks
Secondary Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03 up to 12 months
Secondary Response rate by immune-related response criteria (irRC) 12 weeks
Secondary Overall survival (OS) and progression-free survival (PFS) up to 12 months
Secondary Changes in number of copies of circulating tumor DNA in patients enrolled on this study up to 12 months
Secondary Changes to pixel intensity identified on imaging that is done per routine practice up to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1